Clinical trials
Lung Cancer (Diagnosis) clinical trials
Below are recruiting lung cancer (diagnosis) clinical trials, each written for real people, not researchers. We’re tracking 762 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06745882RecruitingPhase 2
Pembrolizumab for Black Patients with Advanced Lung Cancer
This study tests if the drug pembrolizumab (Keytruda), alone or with chemotherapy, works well for Black patients with advanced non-small cell lung cancer (NSCLC) who haven't had treatment yet. The goal is to see real-world results in this group.
Tampa, FloridaAges 18 years+ - NCT04165070RecruitingPhase 1/Phase 2
Stage IV lung cancer trial using pembrolizumab with or without chemotherapy
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
Gilbert, ArizonaAges 18 years+ - NCT06726148RecruitingPhase 1/Phase 2
Study of ECI830 for advanced breast cancer and solid tumors
This trial is testing a new drug called ECI830, either alone or with another drug, for people with advanced breast cancer or other solid tumors that have not responded to standard treatments. It may be an option if you have HR+/HER2- breast cancer, small cell lung cancer, or a tumor with a specific gene change (CCNE1 amplification).
Los Angeles, CaliforniaAges 18–100 - NCT06772454Recruiting
Testing a new drug combo for advanced lung cancer with COPD
This trial tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy and inhaled steroids helps people with advanced lung cancer who also have COPD. The goal is to see if this combination improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Birmingham, AlabamaAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
Gilbert, ArizonaAges 18 years+ - NCT07230691Recruiting
Study of amivantamab for advanced EGFR-mutated lung cancer
This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.
GrazAges 18 years+ - NCT07779005Recruiting
Lung cancer risk factors study
This study is looking at people who have been newly diagnosed with lung cancer to learn more about what causes it and how it progresses. By participating, you can help researchers find better ways to prevent and treat this disease.
Shenyang, LiaoningAges 18–75 - NCT06901817RecruitingPhase 2
Study of pemetrexed plus nivolumab for lung cancer that has spread to the lining of the brain
This trial tests a combination of two drugs, pemetrexed and nivolumab, given directly into the fluid around the brain and spinal cord. It is for people with a specific type of lung cancer (non-squamous non-small cell) that has spread to the lining of the brain and has not responded to other treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06269211RecruitingPhase 2
Immunotherapy before surgery for EGFR-mutated lung cancer
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
Guangzhou, GuangdongAges 18 years+ - NCT07488923RecruitingPhase 1
ML261 CAR T therapy for advanced small cell lung cancer and related neuroendocrine cancers
This trial tests a new treatment called ML261, which uses your own immune cells (T cells) that have been modified to target DLL3, a protein found on certain cancer cells. It is for people with advanced small cell lung cancer or other neuroendocrine cancers that have not responded to standard treatments.
St Louis, MissouriAges 18 years+ - NCT06939127RecruitingPhase 2
Cold therapy, immunotherapy, and chemo before and after lung cancer surgery
This trial tests a treatment that uses extreme cold (cryoablation) along with immunotherapy (tislelizumab) and chemotherapy before and after surgery for people with early-stage lung cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
TianjinAges 18–75 - NCT05456841Recruiting
Empathic communication training for lung cancer care
This trial tests whether training healthcare providers in empathetic communication improves their interactions with people receiving lung cancer care. You may be invited because your doctor’s clinic is participating and you meet the patient and language requirements.
Irvine, CaliforniaAges 18–100 - NCT05212103Enrolling by invitation
PET scan study for specific cancers using a new tracer
This study uses a PET scan with a special radioactive tracer (68Ga-DOTA-Siglec-9) to look at cancer in certain people. It may help doctors better see cancer-related activity and guide treatment planning for selected cancers.
TurkuAges 18–100 - NCT06626178Recruiting
AI for preventing smoking-related diseases
This study uses artificial intelligence to analyze CT scans and other health data to better identify people at risk for smoking-related diseases like lung cancer. Researchers hope to improve early detection and prevention.
MilanAges 18 years+ - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT06626243Recruiting
Comparing surgery types for lung cancer after pre-surgery therapy
This trial compares different surgical methods (robotic, VATS, or open surgery) used to remove lung cancer after patients have had chemotherapy and/or immunotherapy before their operation. It looks at results from five specialized hospitals to help understand which approach may work best.
Miami, FloridaAges 18 years+ - NCT05254184RecruitingPhase 1
Vaccine and immunotherapy for KRAS-mutated lung cancer
This Phase 1 study tests a KRAS-targeted vaccine combined with chemo and immunotherapy (nivolumab and ipilimumab) for people with advanced non-small cell lung cancer. It aims to help the immune system recognize and fight tumors with specific KRAS mutations, and to see if the treatment is safe and effective enough to study further.
Baltimore, MarylandAges 18–100 - NCT06768307RecruitingPhase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06457906RecruitingPhase 3
Focused radiation vs whole brain radiation for up to 10 lung cancer brain spots
This trial compares two types of radiation for people with small cell lung cancer that has spread to the brain (10 or fewer spots). One approach uses focused radiation only on the tumors, the other treats the whole brain while trying to protect memory. The goal is to see which works better with fewer side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT06974981Recruiting
Using lung cancer screening to find and treat COPD
This study looks at how lung cancer screening can also help find and manage COPD, a lung condition that often goes undetected. If you are a current or former smoker and meet certain age and smoking history criteria, you may join to help improve screening and care for both lung cancer and COPD.
Philadelphia, PennsylvaniaAges 50–80 - NCT07195695RecruitingPhase 3
Zongertinib after surgery for HER2-mutated lung cancer
This trial tests a new pill, zongertinib, against standard of care for people with early-stage (II–IIIB) non-small cell lung cancer that has a specific HER2 mutation in the tyrosine kinase domain. The goal is to see if zongertinib can prevent the cancer from coming back after complete surgical removal.
Fresno, CaliforniaAges 18 years+ - NCT06385262RecruitingPhase 2
Chemo before surgery for early-stage lung cancer
This study tests whether giving chemotherapy before surgery helps people with non-small cell lung cancer that has not spread far. The goal is to see if it can shrink the tumor and improve outcomes.
Durham, North CarolinaAges 18 years+ - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Duarte, CaliforniaAges 18 years+
Hear when a new Lung Cancer (Diagnosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (diagnosis)?
- Yes. Clin2 currently lists 762 recruiting lung cancer (diagnosis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (diagnosis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (diagnosis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.